Indications for endovascular treatment of femoropopliteal (FP) lesions have steadily increased over the past decade. Accordingly, the number of devices has also increased but the choice of the best endovascular treatment remains to be defined. The aim of this meta-analysis was to summarize all studies investigating endovascular treatment of FP lesions greater than 150 mm from 2010 to 2021.
Methods:
Articles were searched using PubMed, Scopus, and Cochrane. Included studies were randomized controlled trials (RCTs), cohort studies, and case series (prospective and retrospective) that evaluated any endovascular procedure in patients with long FP lesions classified TASC (Trans-Atlantic Inter-Society Consensus document II on management of peripheral arterial disease) C and/or D, and a mean length >150 mm, primary outcome had to be the 1-year primary patency. Overall estimate of primary patency, secondary patency, and freedom from target lesion revascularization (TLR) at 1 year depending on the different devices were investigated. The meta-analysis was conducted following the requirements of the MOOSE (Meta-analysis of Observational Studies in Epidemiology) checklist.
Results:
Forty-four papers comprising 4847 patients and 5282 treated limbs were included. Mean lesions length ranged from 150.5 to 330 mm. The pooled 1-year primary and secondary patencies, and freedom from TLR rates were 0.71 (95% CI: 0.67–0.74), 0.87 (95% CI: 0.83–0.91), and 0.79 (95% CI: 0.74–0.84), respectively. Primary permeability at 1 year were 0.68 (95% CI: 0.62–0.73), 0.67 (95% CI: 0.60–0.74), 0.74 (95% CI: 0.64–0.84), and 0.83 (95% CI: 0.78–0.88) for bare metal stents, covered stents (CSs), drug-eluting stents, and drug-coated balloons (DCBs), respectively. Lesions treated with DCB had the highest 1-year primary patency rate.
Conclusions:
At 1-year, endovascular procedures for FP lesions greater than 150 mm obtain satisfactory results. High primary patency rates were obtained with drug-coated devices, while CSs obtained less favorable results. Randomized studies comparing different devices in the treatment of long FP lesions remain necessary to determine the most optimal approach for the management of these patients.
Clinical Impact
This paper highlights on the one hand the satisfactory results of endovascular treatment on complex femoropopliteal lesions formerly reserved for conventional surgery. On the other hand, among the available devices, paclitaxel-eluting devices seem to show superior results which should make them recommended as first-line treatment.
AboyansVRiccoJBBartelinkMLEL, et al. 2017ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.
2.
EnzmannFKNierlichPAspalterM, et al. Nitinol stent versus bypass in long femoropopliteal lesions: 2-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2019;12(24):2541–2549.
3.
ReijnenMMPJvan WalravenLAFritschyWM, et al. 1-year results of a multicenter randomized controlled trial comparing heparin-bonded endoluminal to femoropopliteal bypass. JACC Cardiovasc Interv. 2017;10(22):2320–2331.
4.
BosiersMSetacciCDe DonatoG, et al. ZILVERPASS study: ZILVER PTX stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther off J Int Soc Endovasc Spec. 2020;27(2):287–295.
5.
GiannopoulosSLydenSPBisdasT, et al. Endovascular intervention for the treatment of Trans-Atlantic Inter-Society Consensus (TASC) D femoropopliteal lesions: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2021;22:52–65.
6.
BisdasTBeropoulisEArgyriouA, et al. 1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty. JACC Cardiovasc Interv. 2018;11(10):957–966.
7.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc7(24):e011245. https://www.ahajournals.org/doi/10.1161/JAHA.118.011245
8.
DelooseKBosiersMPeetersP, et al. Combining the Passeo-18 lux drug-coated balloon and the Pulsar-18 bare metal stent: 12- and 24-month outcomes of the BIOLUX 4EVER investigator-initiated trial. J Endovasc Ther off J Int Soc Endovasc Spec. 2020;27(6):936–945.
9.
StroupDFBerlinJAMortonSC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
10.
WellsGSheaBO’ConnellD, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Disponible Sur. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed August 1, 2021.
11.
BaujatBMahéCPignonJP, et al. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21(18):2641–2652.
12.
AstarcıogluMAKılıtCSenT, et al. One-year results of primary stenting for TASC II D lesions of the superficial femoral and popliteal arteries. Acta Cardiol. 2017;72(1):36–40.
13.
ZellerTPeetersPBosiersM, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial. J Endovasc Ther off J Int Soc Endovasc Spec. 2014;21(6):765–774.
14.
BrouilletJDelooseKGouefficY, et al. Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients. J Cardiovasc Surg (Torino). 2018;59(3):392–404.
15.
SaxonRRChervuAJonesPA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol JVIR. 2013;24(2):165–173; quiz 174.
16.
PalenaLMDiaz-SandovalLJSultatoE, et al. Feasibility and 1-year outcomes of subintimal revascularization with supera® stenting of long femoropopliteal occlusions in critical limb ischemia: the “supersub” study. Catheter Cardiovasc Interv off J Soc Card Angiogr Interv. 2017;89(5):910–920.
17.
MicariANerlaRVadalàG, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study. JACC Cardiovasc Interv. 2017;10(7):728–734.
18.
GolzarJSogaYBabaevA, et al. Effectiveness and safety of a paclitaxel-eluting stent for superficial femoral artery lesions up to 190 mm: one-year outcomes of the single-arm IMPERIAL long lesion substudy of the Eluvia drug-eluting stent. J Endovasc Ther. 2020;27(2):296–303.
19.
ElmahdyMFBuonamiciPTrapaniM, et al. Long-term primary patency rate after nitinol self-expandable stents implantation in long, totally occluded femoropopliteal (TASC II C & D) lesions. Heart Lung Circ. 2017;26(6):604–611.
20.
BosiersMDelooseKCallaertJ, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54(4):1042–1050.
21.
BosiersMPeetersPTessarekJ, et al. The Zilver® PTX® single arm study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54(1):115–122.
22.
DavaineJMQueratJKaladjiA, et al. Treatment of TASC C and D femoropoliteal lesions with paclitaxel eluting stents: 12 month results of the STELLA-PTX registry. Eur J Vasc Endovasc Surg. 2015;50(5):631–637.
23.
DavaineJMQuératJGuyomarchB, et al. Primary stenting of TASC C and D femoropopliteal lesions: results of the STELLA register at 30 months. Ann Vasc Surg. 2014;28(7):1686–1696.
24.
KuhanGAbisiSBraithwaiteBD, et al. Early results with the use of heparin-bonded stent graft to rescue failed angioplasty of chronic femoropopliteal occlusive lesions: TASC D lesions have a poor outcome. Cardiovasc Intervent Radiol. 2012;35(5):1023–1028.
25.
BöhmeTNooryEKlausB, et al. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: 36-month results of the viabahn 25 cm trial. J Endovasc Ther. 2021;28(2):222–228.
26.
YuXZhangXLaiZ, et al. One-year outcomes of drug-coated balloon treatment for long femoropopliteal lesions: a multicentre cohort and real-world study. BMC Cardiovasc Disord. 2021;21(1):326.
27.
KimSJKimWKimJB, et al. Determinants of procedural success and patency following subintimal angioplasty in patients with TASC C and D femoropopliteal arterial disease. Circ J. 2010;74(9):1959–1964.
28.
UhlCDadrasAReichmannF, et al. Long-term results of the heparin-bonded Viabahn stent graft in femoropopliteal TASC C and D lesions with a covered stent length of minimum 25 cm. Vascular. 2019;27(5):553–559.
29.
Torres-BlancoÁEdo-FletaGGómez-PalonésF, et al. Mid-term outcomes of endovascular treatment for TASC-II D femoropopliteal occlusive disease with critical limb ischemia. Cardiovasc Intervent Radiol. 2016;39(3):344–352.
30.
SogaYIidaOHiranoK, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52(3):608–615.
31.
SchmidtAPiorkowskiMGörnerH, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9(7):715–724.
32.
NiQYangSXueG, et al. Viabahn stent graft for the endovascular treatment of occlusive lesions in the femoropopliteal artery: a retrospective cohort study with 4-year follow-up. Ann Vasc Surg. 2020;66:573–579.
33.
MyintMSchoutenOBourkeV, et al. A real-world experience with the supera interwoven nitinol stent in femoropopliteal arteries: midterm patency results and failure analysis. J Endovasc Ther. 2016;23(3):433–441.
34.
Montero-BakerMZiomekGJLeonL, et al. Analysis of endovascular therapy for femoropopliteal disease with the Supera stent. J Vasc Surg. 2016;64(4):1002–1008.
35.
MohrPJOyamaJKLuuJT, et al. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis. Cardiovasc Revasc Med Mol Interv. 2015;16(8):465–468.
36.
LichtenbergMStahlhoffWBoeseD.Superficial femoral artery TASC D registry: twelve-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013;54(4):433–439.
37.
LensveltMMAFritschyWMvan OostayenJA, et al. Results of heparin-bonded ePTFE-covered stents for chronic occlusive superficial femoral artery disease. J Vasc Surg. 2012;56(1):118–125.
38.
LaiZZhangXShaoJ, et al. One-year results of drug-coated balloons for long and occlusive Femoropopliteal artery disease: a single-arm trial. BMC Cardiovasc Disord. 2020;20(1):65.
39.
KangWYCampiaUDidierRJ, et al. A single center experience of Zilver PTX for femoro-popliteal lesions. Cardiovasc Revascularization Med Mol Interv. 2016;17(6):399–403.
40.
IidaOSogaYHiranoK, et al. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis. J Endovasc Ther off J Int Soc Endovasc Spec. 2011;18(6):753–761.
41.
GuoXXueGHuangX, et al. Outcomes of endovascular treatment for patients with TASC II D femoropopliteal occlusive disease: a single center study. BMC Cardiovasc Disord. 2015;15:44.
42.
FujiharaMUtsunomiyaMHigashimoriA, et al. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease. Heart Vessels. 2016;31(2):152–157.
43.
BresciaAAWickersBMCorreaJC, et al. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015;61(6):1472–1478.
44.
BiagioniRBBrandãoGDBiagioniLC, et al. Endovascular treatment of TransAtlantic Inter-Society Consensus II D femoropopliteal lesions in patients with critical limb ischemia. J Vasc Surg. 2019;69(5):1510–1518.
45.
LabedPGonzalezFJayetJ, et al. Endovascular treatment of long femoropopliteal lesions with contiguous bare metal stents. Ann Vasc Surg. 2021;76:276–284.
46.
BarilDTChaerRARheeRY, et al. Endovascular interventions for TASC II D femoropopliteal lesions. J Vasc Surg. 2010;51(6):1406–1412.
47.
GrenvilleJLTanKTMoshonovH, et al. Endovascular first strategy for de novo TransAtlantic Inter-Society Consensus C and D femoro-popliteal disease: mid-term outcomes from a single tertiary referral center. Vascular. 2015;23(1):31–40.
48.
DuXWangFWuDM, et al. Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics. Medicine (Baltimore). 2019;98(13):e14840.
49.
GeraghtyPJMewissenMWJaffMR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58(2):386–395.e4.
50.
GabrielliRRosatiMSVitaleS, et al. Randomized controlled trial of remote endarterectomy versus endovascular intervention for TransAtlantic Inter-Society Consensus II D femoropopliteal lesions. J Vasc Surg. 2012;56(6):1598–1605.
51.
LammerJZellerTHauseggerKA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62(15):1320–1327.
52.
FarberA.Chronic limb-threatening ischemia. N Engl J Med. 2018;379(2):171–180.
53.
AdamDJBeardJDClevelandT, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet Lond Engl. 2005;366(9501):1925–1934.
54.
FarberARosenfieldKMenardM.The BEST-CLI trial: a multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia. Tech Vasc Interv Radiol. 2014;17(3):221–224.
55.
GouëfficYSauguetADesgrangesP, et al. A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE trial. JACC Cardiovasc Interv. 2020;13(4):447–457.
56.
GrayWAKeirseKSogaY, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet Lond Engl. 2018;392(10157):1541–1551.
57.
ScheinertDMicariABrodmannM, et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv. 2018;11(10):e005654.
58.
DakeMDAnselGMJaffMR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the zilver PTX randomized trial. Circulation. 2016;133(15):1472–1483; discussion 1483.
59.
ZorgerNMankeCLenhartM, et al. Peripheral arterial balloon angioplasty: effect of short versus long balloon inflation times on the morphologic results. J Vasc Interv Radiol JVIR. 2002;13(4):355–359.
60.
GarciaLARosenfieldKRMetzgerCD, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89(7):1259–1267.
61.
KatsogridakisEBallanceLCawleyO, et al. Drug-eluting stents for the treatment of complex femoro-popliteal disease: a systematic review and meta-analysis. J Cardiovasc Surg (Torino). 2022;63:299–307.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
